Status:
COMPLETED
Antibiotics Treatment of Cholangitis Post-Kasai Portoenterostomy
Lead Sponsor:
Tongji Hospital
Collaborating Sponsors:
Shanghai Children's Hospital
Conditions:
Cholangitis, Secondary Biliary
Treatment Compliance
Eligibility:
All Genders
3-2 years
Phase:
PHASE4
Brief Summary
Application of multi-center, prospective study on the severity of postoperative cholangitis biliary atresia classification, according to the degree of cholangitis targeted therapy, to improve the ther...
Detailed Description
Cholangitis patients post-kasai Portoenterostomy were grouped by cholangitis severity score, according to the severity was divided into mild, moderate, severe cholangitis, all levels of cholangitis pa...
Eligibility Criteria
Inclusion
- Age 3 months to 2 years old, gender is not limited.
- Patients with cholangitis post-kasai Portoenterostomy.
- No other treatment before entering the group.
- The patient must sign an informed consent form and can actively cooperate with the treatment and follow-up.
Exclusion
- Patients with other infectious lesions.
- Patients with other severe deformity.
- Patients with end-stage liver failure.
- Patientsn with liver transplantation.
- Patients with mental symptoms or other disease.
Key Trial Info
Start Date :
May 1 2021
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
April 1 2022
Estimated Enrollment :
160 Patients enrolled
Trial Details
Trial ID
NCT04370145
Start Date
May 1 2021
End Date
April 1 2022
Last Update
April 11 2022
Active Locations (2)
Enter a location and click search to find clinical trials sorted by distance.
1
Tongji hospital affiliated to tongji medical college of huazhong university of science and technology
Wuhan, Hubei, China, 430030
2
TongjiHospital
Wuhan, Hubei, China, 430030